BR112014017426A2 - formulação de quitosana glicada viscoelástica, método para o tratamento do câncer, composição, imunoadjuvante, e, método para destruir a neoplasia de forma fotofísica, e ao mesmo tempo gerar uma vacina autóloga in situ - Google Patents
formulação de quitosana glicada viscoelástica, método para o tratamento do câncer, composição, imunoadjuvante, e, método para destruir a neoplasia de forma fotofísica, e ao mesmo tempo gerar uma vacina autóloga in situInfo
- Publication number
- BR112014017426A2 BR112014017426A2 BR112014017426A BR112014017426A BR112014017426A2 BR 112014017426 A2 BR112014017426 A2 BR 112014017426A2 BR 112014017426 A BR112014017426 A BR 112014017426A BR 112014017426 A BR112014017426 A BR 112014017426A BR 112014017426 A2 BR112014017426 A2 BR 112014017426A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunoadjuvant
- neoplasm
- situ
- composition
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Otolaryngology (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Electromagnetism (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
1 / 1 resumo âformulaãão de quitosana glicada viscoelãstica, mãtodo para o tratamento do cãncer, composiãão, imunoadjuvante, e, mãtodo para destruir a neoplasia de forma fotofãsica, e ao mesmo tempo gerar uma vacina autãloga in situâ o presente invento refere-se genericamente a composiã§ãµes terapãªuticas compreendendo composiã§ãµes de derivados de quitosana, sã£o usadas em conexã£o com mã©todos para o tratamento de neoplasmas, como ã© o caso dos neoplasmas malignos do pulmã£o, tirã³ide e rim, de outros tipos de tumores malignos, e de outras desordens mã©dicas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261588783P | 2012-01-20 | 2012-01-20 | |
US61/588,783 | 2012-01-20 | ||
PCT/US2013/021903 WO2013109732A2 (en) | 2012-01-20 | 2013-01-17 | Chitosan-derived compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014017426A2 true BR112014017426A2 (pt) | 2017-06-13 |
BR112014017426A8 BR112014017426A8 (pt) | 2017-07-04 |
BR112014017426B1 BR112014017426B1 (pt) | 2021-12-28 |
Family
ID=48799808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014017426-1A BR112014017426B1 (pt) | 2012-01-20 | 2013-01-17 | Formulação de quitosana glicada viscoelástica, composição farmacêutica, composição e imunoadjuvante |
Country Status (30)
Country | Link |
---|---|
US (1) | US20150018748A1 (pt) |
EP (2) | EP3831393A1 (pt) |
JP (1) | JP6180436B2 (pt) |
KR (5) | KR20200139254A (pt) |
CN (2) | CN110038125A (pt) |
AU (1) | AU2013209716B2 (pt) |
BR (1) | BR112014017426B1 (pt) |
CA (1) | CA2861367C (pt) |
CL (1) | CL2014001880A1 (pt) |
CO (1) | CO7101239A2 (pt) |
CY (1) | CY1123490T1 (pt) |
DK (1) | DK2804611T3 (pt) |
EA (1) | EA030148B1 (pt) |
EC (1) | ECSP14014778A (pt) |
ES (1) | ES2829899T3 (pt) |
HK (1) | HK1210019A1 (pt) |
HR (1) | HRP20201647T1 (pt) |
HU (1) | HUE051744T2 (pt) |
IL (1) | IL233649B (pt) |
LT (1) | LT2804611T (pt) |
MX (1) | MX371275B (pt) |
MY (1) | MY191932A (pt) |
NZ (1) | NZ628433A (pt) |
PE (1) | PE20142325A1 (pt) |
PL (1) | PL2804611T3 (pt) |
PT (1) | PT2804611T (pt) |
RS (1) | RS61257B1 (pt) |
SG (1) | SG11201403943TA (pt) |
SI (1) | SI2804611T1 (pt) |
WO (1) | WO2013109732A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11773188B2 (en) | 2012-01-20 | 2023-10-03 | Immunophotonics, Inc | Chitosan-derived compositions |
US11111316B2 (en) * | 2012-01-20 | 2021-09-07 | Immunophotonics, Inc. | Chitosan-derived compositions |
US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
CN107200788B (zh) * | 2017-05-11 | 2020-04-14 | 暨南大学 | 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用 |
US20200010575A1 (en) * | 2018-07-05 | 2020-01-09 | Immunophotonics, Inc. | Semi-synthetic biopolymers for use in treating proliferative disorders |
WO2020060131A1 (ko) * | 2018-09-19 | 2020-03-26 | 주식회사 엘지화학 | LiOH를 포함하는 리튬 이차 전지용 전극, 그의 제조방법, 및 상기 전극을 포함하는 리튬 이차 전지 |
EP3817773A4 (en) | 2018-11-26 | 2021-09-15 | Forty Seven, Inc. | HUMANIZED ANTIBODIES AGAINST C-KIT |
WO2023028311A1 (en) * | 2021-08-27 | 2023-03-02 | Immunophotonics, Inc. | Glycated chitosans for treatment of viral infections |
WO2024133580A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Medical products containing an aqueous formulation of a peptide |
WO2024133588A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Compositions comprising an oncolytic peptide and chitosan |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US591200A (en) | 1897-10-05 | Safe-lock | ||
US4424346A (en) * | 1981-06-04 | 1984-01-03 | Canadian Patents And Development Ltd. | Derivatives of chitins, chitosans and other polysaccharides |
US5095030A (en) | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5002962A (en) | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
US5214036A (en) | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
US5283225A (en) | 1992-11-24 | 1994-02-01 | Eastman Kodak Company | Underlayer of dye-donor element for thermal dye transfer systems |
US5912000A (en) * | 1994-09-23 | 1999-06-15 | Zonagen, Inc. | Chitosan induced immunopotentiation |
US6316007B1 (en) * | 1995-04-04 | 2001-11-13 | Wound Healing Of Oklahoma | Combined physical and immunotherapy for cancer |
WO1996031237A2 (en) * | 1995-04-04 | 1996-10-10 | Wound Healing Of Oklahoma | Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant |
TW389694B (en) * | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
JP4606586B2 (ja) * | 1998-11-10 | 2011-01-05 | 株式会社ネーテック | 機能性キトサン誘導体 |
US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
US20040047892A1 (en) * | 2000-11-15 | 2004-03-11 | Desrosiers Eric Andre | Filler composition for soft tissue augmentation and reconstructive surgery |
US6756363B1 (en) * | 2000-11-17 | 2004-06-29 | Wound Healing Of Oklahoma, Inc. | Solutions and films of glycated chitosan |
US20110130473A1 (en) * | 2007-11-13 | 2011-06-02 | Bio-Technology General (Israel) Ltd. | Dilute filtration sterilization process for viscoelastic biopolymers |
CN101440136B (zh) * | 2008-12-12 | 2011-07-06 | 中国海洋大学 | 胺糖化几丁聚糖复合物的制备方法 |
-
2013
- 2013-01-17 CN CN201910104579.9A patent/CN110038125A/zh active Pending
- 2013-01-17 WO PCT/US2013/021903 patent/WO2013109732A2/en active Application Filing
- 2013-01-17 PE PE2014001126A patent/PE20142325A1/es not_active Application Discontinuation
- 2013-01-17 EA EA201491402A patent/EA030148B1/ru not_active IP Right Cessation
- 2013-01-17 PT PT137385050T patent/PT2804611T/pt unknown
- 2013-01-17 CN CN201380006011.4A patent/CN104619310A/zh active Pending
- 2013-01-17 RS RS20201245A patent/RS61257B1/sr unknown
- 2013-01-17 NZ NZ628433A patent/NZ628433A/en unknown
- 2013-01-17 KR KR1020207034027A patent/KR20200139254A/ko not_active IP Right Cessation
- 2013-01-17 SG SG11201403943TA patent/SG11201403943TA/en unknown
- 2013-01-17 KR KR1020177007047A patent/KR20170032490A/ko active Search and Examination
- 2013-01-17 ES ES13738505T patent/ES2829899T3/es active Active
- 2013-01-17 KR KR1020147021861A patent/KR20140117487A/ko active Search and Examination
- 2013-01-17 JP JP2014553403A patent/JP6180436B2/ja active Active
- 2013-01-17 MX MX2014008702A patent/MX371275B/es active IP Right Grant
- 2013-01-17 US US14/372,586 patent/US20150018748A1/en not_active Abandoned
- 2013-01-17 KR KR1020187032309A patent/KR20180123727A/ko not_active Application Discontinuation
- 2013-01-17 BR BR112014017426-1A patent/BR112014017426B1/pt active IP Right Grant
- 2013-01-17 EP EP20198582.7A patent/EP3831393A1/en active Pending
- 2013-01-17 EP EP13738505.0A patent/EP2804611B1/en active Active
- 2013-01-17 AU AU2013209716A patent/AU2013209716B2/en active Active
- 2013-01-17 CA CA2861367A patent/CA2861367C/en active Active
- 2013-01-17 PL PL13738505T patent/PL2804611T3/pl unknown
- 2013-01-17 KR KR1020227005616A patent/KR20220028153A/ko not_active Application Discontinuation
- 2013-01-17 HU HUE13738505A patent/HUE051744T2/hu unknown
- 2013-01-17 DK DK13738505.0T patent/DK2804611T3/da active
- 2013-01-17 MY MYPI2014701927A patent/MY191932A/en unknown
- 2013-01-17 SI SI201331814T patent/SI2804611T1/sl unknown
- 2013-01-17 LT LTEP13738505.0T patent/LT2804611T/lt unknown
-
2014
- 2014-07-15 IL IL233649A patent/IL233649B/en active IP Right Grant
- 2014-07-15 CL CL2014001880A patent/CL2014001880A1/es unknown
- 2014-07-18 CO CO14156300A patent/CO7101239A2/es unknown
- 2014-08-19 EC ECIEPI201414778A patent/ECSP14014778A/es unknown
-
2015
- 2015-10-30 HK HK15110753.9A patent/HK1210019A1/xx unknown
-
2020
- 2020-10-13 HR HRP20201647TT patent/HRP20201647T1/hr unknown
- 2020-11-06 CY CY20201101048T patent/CY1123490T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014017426A8 (pt) | formulação de quitosana glicada viscoelástica, método para o tratamento do câncer, composição, imunoadjuvante, e, método para destruir a neoplasia de forma fotofísica, e ao mesmo tempo gerar uma vacina autóloga in situ | |
CY1121882T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
EP4140487A8 (en) | Combination therapy for treating cancer | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
BR112015022588A2 (pt) | composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo | |
CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
MX2021008224A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
MX366503B (es) | Derivados de amatoxina. | |
AU2018270408A1 (en) | Methods of inhibiting aging and treating aging-related disorders | |
EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
GB201209613D0 (en) | New compounds | |
WO2014194254A9 (en) | Treatment of cancers using pi3 kinase isoform modulators | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
BR112015011147A8 (pt) | composto, composição farmacêutica, e, uso do referido composto | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
CA2908742C (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
UA116053C2 (uk) | Застосування похідних бензоімідазолу-проліну | |
BR112016010072A8 (pt) | conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado | |
CY1122935T1 (el) | Ενισχυτικα της υδατοδιαλυτοτητας που βασιζονται στο γλυκογονο |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/01/2013, OBSERVADAS AS CONDICOES LEGAIS. |